IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES
Mcinnes IB, Wallman JK, Schett G, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Book Volume: 58
DOI: 10.1093/rheumatology/kez107.070
Authors with CRIS profile
Involved external institutions
Lund University / Lunds universitet
Sweden (SE)
Novartis AG
Switzerland (CH)
University of Glasgow
United Kingdom (GB)
Novartis Sverige AB
Sweden (SE)
RTI Health Solutions
United States (USA) (US)
Sweden (SE)
Novartis AG
Switzerland (CH)
University of Glasgow
United Kingdom (GB)
Novartis Sverige AB
Sweden (SE)
RTI Health Solutions
United States (USA) (US)
How to cite
APA:
Mcinnes, I.B., Wallman, J.K., Schett, G., Quebe-Fehling, E., Rasouliyan, L., Pricop, L.,... Gaillez, C. (2019). IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES.
MLA:
Mcinnes, Iain B., et al. "IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES." 2019.
BibTeX: Download